Sermorelin
Growth hormone–releasing hormone (GHRH) analog
Quick Answer
A synthetic 29-amino-acid fragment of human GHRH — one of the earliest GHRH-pathway peptides to reach the market, and the one with the longest FDA-approval history of any compound in this library, even though that approved product is no longer sold.
Why People Are Interested
It's one of the few GHRH-pathway peptides with a real, documented FDA approval history — which makes it a frequent reference point in "is this legal/approved" discussions, even though the specific approved product isn't available anymore and current use is compounded.
What People Hope It May Do
Broader adult hormone-support, recovery, sleep, and body-composition benefits beyond its originally-approved pediatric GH-deficiency indication. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Pituitary function testing in adults and children
Adult growth-hormone-deficiency and aging-related hormone-support protocols (largely off-label, compounded use)
Comparative pharmacology against newer GHRH analogs and secretagogues in this library (tesamorelin, CJC-1295, ipamorelin)
How It May Work
Binds the GHRH receptor on the pituitary gland, stimulating the body's own pulsatile release of growth hormone through the natural feedback pathway, rather than supplying growth hormone directly.
What Human Research Shows
The original FDA approval was supported by clinical trials sufficient to establish safety and effectiveness for its specific approved uses in the 1990s. Since the branded product's discontinuation, most current human use is off-label and compounded, with far less rigorous, non-FDA-reviewed evidence behind that use.
What Preclinical Research Shows
Standard preclinical pharmacology/toxicology package that preceded its original 1990s FDA approval; no meaningful new preclinical program has been run since.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to Sermorelin is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving Sermorelin, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
General information only — not individualized guidance. The original approved product's labeling covered pituitary/GH-axis effects and injection-site reactions; compounded versions do not carry FDA-reviewed labeling, and quality can vary by pharmacy. Actual use requires a licensed provider.
Regulatory Status
Sermorelin acetate was FDA-approved twice: as Geref (0.05 mg ampules, NDA 19-863, approved December 1990) for evaluating pituitary gland growth-hormone response, and as Geref Diagnostic/therapeutic vials (0.5 mg and 1.0 mg, NDA 20-443, approved September 1997) for treating growth hormone deficiency in children. The manufacturer, EMD Serono, discontinued the product for business reasons in 2008; a 2013 FDA Federal Register determination explicitly found it was not withdrawn for safety or effectiveness reasons. No FDA-approved sermorelin product is currently marketed in the US — all current sermorelin sold is compounded, which means it has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality the way the original approved product was.
What We Still Don't Know
Whether the clinical trial evidence behind the discontinued approved product generalizes to the adult, off-label, compounded use that makes up nearly all current sermorelin use — and what quality variability exists across compounding pharmacies since there's no FDA-reviewed manufacturing standard for the compounded product.
Limitations of Evidence
The strongest evidence (sufficient for two FDA approvals) applies to a product that is no longer manufactured. Current compounded use rests on that older evidence plus off-label clinical experience, not new FDA-reviewed trials in the populations now most commonly using it (adults seeking hormone support, rather than the originally-approved pediatric GH-deficiency population).
Keep Researching
- Search ClinicalTrials.gov for Sermorelin
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-08-17